Search

Displaying results 3611 - 3620 of 9670 in total
  1. Drug

    Gemtuzumab ozogamicin

    go.drugbank.com/drugs/DB00056
    ApprovedInvestigational

    However, it was voluntarily withdrawn from the market in 2010 due to safety concerns, increased patient deaths and insufficient evidence of clinical benefit during confirmatory trials [L941]. … Marketing approval of gemtuzumab ozogamicin was granted on May 17, 2000 by FDA as a treatment for patients with CD33-positive AML in first relapse who are 60 years of age or older and who are not considered

    Products: MYLOTARG POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 5MG/VIAL
  2. Drug

    Elymus repens pollen

    go.drugbank.com/drugs/DB10489
    Approved

    Elymus repens pollen is the pollen of the Elymus repens plant. Elymus repens pollen is mainly used in allergenic testing.

    Mixtures: Treatment Set TS333938, Treatment Set TS128872
  3. Drug

    Triticum aestivum pollen

    go.drugbank.com/drugs/DB10498
    Approved

    Triticum aestivum pollen is the pollen of the Triticum aestivum plant. Triticum aestivum pollen is mainly used in allergenic testing.

    Mixtures: Treatment Set TS333938, Treatment Set TS128872
  4. Drug

    Phalaris arundinacea pollen

    go.drugbank.com/drugs/DB10714
    Approved

    Phalaris arundinacea pollen is the pollen of the Phalaris arundinacea plant. Phalaris arundinacea pollen is mainly used in allergenic testing.

    Mixtures: Treatment Set TS333938, Treatment Set TS128872
  5. Drug

    Secale cereale pollen

    go.drugbank.com/drugs/DB10717
    Approved

    Secale cereale pollen is the pollen of the Secale cereale plant. Secale cereale pollen is mainly used in allergenic testing.

    Mixtures: Treatment Set TS333938, Treatment Set TS128872
  6. Drug

    SO-101

    go.drugbank.com/drugs/DB05345
    Experimental

    Doxepin has been prescribed for more than 40 years for the treatment of depression and anxiety at dosages typically ranging from 75 mg to 300 mg per day.

  7. Drug

    Ethylmorphine

    go.drugbank.com/drugs/DB01466
    IllicitInvestigational

    It is metabolized in the liver by ethylmorphine-N-demethylase and used as an indicator of liver function. It is not marketed in the US but is approved for use in various countries around the world. … In the US it is a schedule II drug (single-entity) and schedule III drug (in combination products).

  8. Drug

    Phenindamine

    go.drugbank.com/drugs/DB01619
    Approved

    Antihistamines such as phenindamine appear to compete with histamine for histamine H1- receptor sites on effector cells. … It is used to treat sneezing, runny nose, itching, watery eyes, hives, rashes, itching, and other symptoms of allergies and the common cold.

  9. Drug

    AX200

    go.drugbank.com/drugs/DB05093
    Investigational

    AX200, which has been developed for the treatment of stroke, is the most advanced drug candidate and is halfway through the process of gaining clinical approval.

  10. Drug

    Catridecacog

    go.drugbank.com/drugs/DB09310
    Approved

    Coagulation Factor XIII A-Subunit (Recombinant) is available in the US as the commmercially available product Tretten, and in the EU as NovoThirteen. … as the endogenously available form.